KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Research & Development (2018 - 2025)

Moderna (MRNA) has disclosed Research & Development for 8 consecutive years, with $775.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 30.93% to $775.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 billion through Dec 2025, down 31.06% year-over-year, with the annual reading at $3.1 billion for FY2025, 31.06% down from the prior year.
  • Research & Development for Q4 2025 was $775.0 million at Moderna, down from $801.0 million in the prior quarter.
  • The five-year high for Research & Development was $1.4 billion in Q4 2023, with the low at $401.0 million in Q1 2021.
  • Average Research & Development over 5 years is $890.3 million, with a median of $838.0 million recorded in 2022.
  • The sharpest move saw Research & Development soared 248.7% in 2021, then tumbled 42.67% in 2025.
  • Over 5 years, Research & Development stood at $648.0 million in 2021, then skyrocketed by 86.88% to $1.2 billion in 2022, then grew by 16.1% to $1.4 billion in 2023, then decreased by 20.2% to $1.1 billion in 2024, then plummeted by 30.93% to $775.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $775.0 million, $801.0 million, and $700.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.